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Introduction
Lung cancer is the most common malignancy in the
world and the leading cause of tumor-related death in
developed countries1. Approximately 80–85% of lung
cancer subtypes are of non-small cell histology. Non-
small cell lung cancer (NSCLC) is also one of the most
common malignant tumors in China. It is usually locally
advanced or advanced in presentation and is rarely
diagnosed at an early stage. Although the median age
of patients with newly diagnosed NSCLC participating
in clinical trials is 60–62 years, more than 50% of cases
of advanced NSCLC are diagnosed in patients ≥65 years,
and approximately 30–40% of cases are diagnosed in
patients ≥ 70 years2,3. Evidence from earlier clinical tri-
als confirms that platinum-based chemotherapy regi-
mens can increase overall survival and improve the
quality of life compared with best supportive care in
patients with advanced NSCLC4. Therefore, platinum-
based combination chemotherapy has become the
standard treatment for patients aged < 70 years with
advanced NSCLC5. Because of the risks associated with
its potential toxicity, however, chemotherapy is often
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withheld from elderly patients. The elderly typically
have a greater number of non-cancer comorbidities
and poorer performance status (PS) at diagnosis than
younger patients with the same extent of disease6.
Moreover, age-related physiologic changes in functional
status, organ function, and pharmacokinetics make the
selection of their optimal treatment more challenging.
Although a consensus is emerging that elderly pa-
tients can benefit from chemotherapy, it is less clear
whether single-agent or combination therapy is prefer-
able, or whether particular agents have advantages for
initial treatment. Several clinical trials with single-agent
therapy of vinorelbine or gemcitabine have shown good
activity and tolerability for elderly patients with ad-
vanced NSCLC7–10. However, the role of platinum-based
combination chemotherapy in elderly patients remains
controversial. To date, prospective phase III trials with
platinum-based chemotherapy for elderly patients are
still lacking. Evidence to support the use of a platinum-
based combination regimen in elderly patients with ad-
vanced NSCLC comes only from retrospective analyses
of the subset of large randomized trials using platinum-
based chemotherapy, which suggested that main treat-
ment outcome did not differ between elderly patients
and younger patients11–13. While awaiting further re-
sults from ongoing clinical trials specifically designed
for elderly patients, evidence from retrospective study
can be helpful. During the past decade, a number of
patients ≥ 70 years with unresectable, locally advanced
and metastatic NSCLC received chemotherapy at our
hospital. In the present study, we reviewed our experi-
ence between 2000 and 2007, with elderly patients
treated with chemotherapy for stage IIIB and IV NSCLC,
and compared the efficacy and toxicity of cisplatin-
based combination regimens (cisplatin plus vinorel-
bine or cisplatin plus gemcitabine) with single-agent
regimens (vinorelbine or gemcitabine) in these patient
populations.
Subjects and Methods
Clinical information was obtained through a detailed
retrospective review of the medical records of all eld-
erly patients who received chemotherapy for stage IIIB
and IV NSCLC at the Affiliated Hospital of Jiangsu
University in China from January 2000 to June 2007.
We limited our analyses only to patients ≥ 70 years who
had been diagnosed with unresectable, locally advanced
and metastatic NSCLC, and who received combination
chemotherapy with cisplatin plus either vinorelbine or
gemcitabine, or single-agent chemotherapy with vino-
relbine or gemcitabine as first-line therapy.
The data recorded included demographic informa-
tion, staging procedure, pretherapy clinical assessment,
and comorbidity number. All patients were staged on
the basis of medical history, physical examination, chest
radiography, fiberoptic bronchoscopy, brain and chest
computed tomography scan, abdominal ultrasound or
abdominal computed tomography scan, and radionu-
clide scan of bone. All patients had histologically or
cytologically proven stage IIIB (with malignant effu-
sion or metastatic supraclavicular lymph nodes) or IV
NSCLC, and had an Eastern Cooperative Oncology Group
PS of ≤ 2, and had radiographically measurable or as-
sessable disease and adequate hematologic, renal and
hepatic function. Patients with brain metastases or
who previously were treated with a biologic response
modifier, or those with a history of other malignant
tumors were excluded from this study. Patients who
had undergone radiotherapy were included in this anal-
ysis provided that chest radiotherapy was performed
in patients with stage IIIB disease without pleural effu-
sion who had an objective response or stable disease
after the completion of three to four cycles of chemo-
therapy, or who had progressive disease at any time
provided that distant metastases had not appeared.
Data on the chemotherapy regimen, number of cycles,
toxicity, objective response, and date of disease pro-
gression and death were collected. Survival data were
last collected in April 2008.
Comorbidities mainly included arrhythmias, hyper-
tension, ischemia cardiopathy, cerebral vascular disease,
chronic obstructive pulmonary disease, mild liver dis-
ease, peptic ulcer, benign prostatic hypertrophy, and
diabetes. Diagnosis of a comorbidity was made accord-
ing to the international criteria of these diseases, based
on relevant examination, such as electrocardiogram,
blood pressure measurement, coronary arteriography,
and brain computed tomography scan or angiography.
Chest radiography was performed before each cycle,
and computed tomography scans were performed every
two or three cycles to evaluate the response to treat-
ment. Brain computed tomography and bone scan were
repeated only if clinically indicated. Tumor response
was assessed according to World Health Organization
criteria. A complete response was defined as the com-
plete disappearance of all clinically detectable tumors
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for at least 4 weeks. A partial response was defined 
as a reduction of ≥ 50% in the product of the largest
perpendicular diameters of one or more measurable
lesions lasting for 4 weeks with no new areas of malig-
nant disease. Stable disease was defined as a < 50%
reduction or a < 25% increase in all measurable lesions
with the appearance of no new lesions. Progressive
disease was defined as a 25% increase in the product
of two perpendicular diameters of any measured lesion
or the development of new lesion. The best response
was recorded for each patient. Toxicity for each cycle
was assessed using the World Health Organization cri-
teria before the beginning of the next cycle, and hema-
tologic toxicity assessment was performed weekly. The
worst data for each patient in all cycles of chemother-
apy were used in the toxicity analysis.
Outcomes were determined from multiple sources
including the medical records, referring physicians,
and patients’ families. Overall survival was calculated
from the date of the first cycle of chemotherapy to the
date of death from any cause or the last follow-up visit.
Progression-free survival was calculated from the date
of the first cycle of chemotherapy to the date of disease
progression, recurrence, or death from any causes. Sur-
vival curves were estimated using the Kaplan-Meier
method. The comparisons of survival time between pa-
tients with different characteristics were performed by
the log-rank test. The χ2 test or the Fisher exact test was
used in the response rate comparison and the toxicity
analysis. Statistical significance was defined as p < 0.05.
Results
Treatment regimen
From January 2000 to June 2007, 146 patients 70 years
and older with stage IIIB or IV NSCLC received chemo-
therapy with combination or single-agent regimens. Of
these, 102 patients were eligible and assessable. The
reason for ineligibility included Eastern Cooperative
Oncology Group PS > 2 (n = 9), brain metastasis (n = 8),
loss to follow-up (n = 6), previous malignant disease
(n = 2), and other chemotherapy regimens including
cisplatin plus etoposide (n = 7), vinorelbine plus gem-
citabine (n=6), cisplatin plus paclitaxel (n=4), and doc-
etaxel (n=2). Characteristics of the 102 patients included
in the present study are listed in Table 1. These 102 pa-
tients were divided into two groups according to che-
motherapy regimens: (1) cisplatin-based combination
group, including the patients treated with cisplatin plus
vinorelbine (cisplatin 60–70 mg/m2 on day 1 and vino-
relbine 20–25 mg/m2 on days 1 and 8 every 3 weeks)
(n = 29) and those with cisplatin plus gemcitabine (cis-
platin 60–70 mg/m2 on day 1 and gemcitabine 800–
1,000mg/m2 on days 1 and 8 every 3 weeks) (n=25); and
(2) single-agent group, including the patients treated
with vinorelbine (vinorelbine 25–30 mg/m2 on days 1,
8 and 15 every 4 weeks) (n = 26) and those with gemc-
itabine (gemcitabine 1,000–1,200 mg/m2 on days 1, 8
and 15 every 4 weeks) (n=22). The doses and regimen
of chemotherapy were used at the discretion of each
treating physician based on patient PS and toxicity.
Changes in dosage were based on hematologic test re-
sults obtained on day 1 of chemotherapy; if neutrophils
were < 1.5 × 109/L, and platelets were < 100 × 109/L,
treatment was delayed by 1 week. Treatment on day 8
had to be cancelled if neutrophil counts were < 1.0 ×
109/L and platelets were < 100 × 109/L. All patients
received an antiemetic prophylaxis that consisted of
5-hydroxytryptamine type 3 receptor antagonists and
dexamethasone, and patients treated with cisplatin-
based combination received adequate hydration.
Patients were treated for a maximum of six cycles or
until intolerable toxicity, progressive disease, or death.
The two groups were well balanced with respect to
the main characteristics (Table 1). Approximately 75%
of the patients were males, and approximately 65% of
the patients had an Eastern Cooperative Oncology
Group PS of 0 or 1. One-third of the patients presented
with stage IIIB disease. In each group, the predominant
histology was squamous-cell carcinoma, and more
patients had metastatic sites of one or two. There were
slightly more patients with one or no comorbidity in
the cisplatin-based combination group than in the 
single-agent group.
Treatment response
The median number of chemotherapy cycles received
was three (range, 1–6) for the cisplatin-based combina-
tion group, and four (range, 1–6) for the single-agent
group. The mean dose intensities were 17.8mg/m2/week
(range, 13.9–22.1 mg/m2/week) and 13.2 mg/m2/week
(range, 11.6–15.1 mg/m2/week) for cisplatin and vi-
norelbine, respectively, for combined treatment, and
18.4 mg/m2/week (range, 13.6–22.7 mg/m2/week) and
526 mg/m2/week (range, 480–576 mg/m2/week) for
cisplatin and gemcitabine, respectively, for combined
treatment. In the singe-agent group, the mean dose
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intensities of vinorelbine and gemcitabine were 18.1mg/
m2/week (range, 14.2–21.8 mg/m2/week) and 745 mg/
m2/week (range, 704–789 mg/m2/week), respectively.
Treatment results and objective response are shown
in Table 2. Objective response could be not evaluated
in 10 patients because of discontinuation before cycle
2 for the following reasons: toxicity (n = 3), patient
refusal (n = 2), early death (n = 1), and unconfirmed
response after the completion of two cycles (n = 4). The
overall response rate (complete response and partial
response) for the cisplatin-based combination group
was 46%, whereas it was 25% for the single-agent group
(p = 0.03).
After the end of first-line chemotherapy, 38 patients
(37%) received second-line therapy because of a lack of
response to first-line therapy, or recurrence or progres-
sion of the disease. Forty-eight percent of patients ini-
tially treated with single-agent chemotherapy received
second-line therapy compared with 28% for patients ini-
tially treated with cisplatin-based combination (p=0.04).
Furthermore, 30% of patients in the single-agent group
received a cisplatin-based combination as second-line
therapy compared with 9% of patients in the cisplatin-
based combination group (p = 0.01). Sixteen patients
(17%) received second-line gefitinib (Table 2). Nine pa-
tients with stage IIIB and supraclavicular lymph nodes
metastases underwent chest radiotherapy after the
completion of three to four cycles of chemotherapy,
five were in the cisplatin-based combination group,
and four were in the single-agent group.
Toxicity
The most relevant toxic events are summarized in
Table 3. The incidences of grade 3 and 4 anemia and
neutropenia were significantly higher in the cisplatin-
based combination group than in the single-agent
Table 1. Patient characteristics*
Cisplatin-based group Single-agent group
Characteristic
C + V (n = 29) C + G (n = 25) V (n = 26) G (n = 22)
Age, median (range), yr 74 (71–79) 73 (70–80) 76 (71–83) 75 (70–81)
Sex
Male 22 (76) 18 (72) 20 (77) 16 (73)
Female 7 (24) 7 (28) 6 (23) 6 (27)
Performance status
0 8 (28) 6 (24) 6 (23) 5 (23)
1 11 (38) 10 (40) 12 (46) 9 (41)
2 10 (34) 9 (36) 8 (31) 8 (36)
Stage
IIIB 9 (31) 8 (32) 8 (31) 6 (27)
IV 20 (69) 17 (68) 18 (69) 16 (73)
Histologic type
Squamous cell carcinoma 16 (55) 14 (56) 15 (58) 13 (59)
Adenocarcinoma 11 (38) 10 (40) 8 (31) 9 (41)
Large cell carcinoma 2 (7) 1 (4) 3 (11) 0 (0)
Metastatic sites
1 to 2 20 (69) 19 (76) 16 (62) 15 (68)
≥ 3 9 (31) 6 (24) 10 (38) 7 (32)
Comorbidities
0 5 (17) 6 (24) 3 (12) 4 (18)
1 10 (34) 8 (32) 7 (27) 6 (27)
2 8 (28) 6 (24) 10 (38) 7 (32)
≥ 3 6 (21) 5 (20) 6 (23) 5 (23)
*Data are presented as n (%). C = cisplatin; V = vinorelbine; G = gemcitabine.
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group (p=0.04 and p=0.02, respectively). However, the
incidence of neutropenia fever was similar between
both arms. There was not a significant difference in
the occurrence of thrombocytopenia and nonhemato-
logic toxicity between two groups, although nausea
and emesis were more common in the cisplatin-based
combination group.
Survival
The median survival time for the entire study popula-
tion was 9.5 months (95% confidence interval, CI, 7.68–
11.42), and the 1- and 2-year survival rates were 31.4%
and 7%, respectively. The median progression-free 
survival of all patients was 6.5 months (95% CI, 5.28–
7.72), and the 1-year progression-free survival rate was
10.5%. The median survival time was 11.1 months (95%
CI, 9.24–12.96) in the cisplatin-based combination
group compared with 8.9 months (95% CI, 7.68–10.14)
in the single-agent group. The 1- and 2-year survival
rates were 38.6% and 9.1%, respectively, in the combina-
tion group compared with 22.4% and 4.8%, respectively,
in the single-agent group (Figure 1). Although there was
no statistically significant difference in overall survival
time between two groups, cisplatin-based chemother-
apy showed a trend toward improved overall survival
(p = 0.06). For the cisplatin-based combination group,
Table 2. Treatment results
Cisplatin-based group (n = 54) Single-agent group (n = 48) p
Chemotherapy cycles
No. of cycles 164 156
Median (range) 3 (1–6) 4 (1–6)
Tumor response
Complete response, n 0 0
Partial response, n 25 12
Stable disease, n 14 20
Progressive disease, n 10 11
Not evaluated, n 5 5
Overall response, n (%) 25 (46) 12 (25) 0.03
Second-line chemotherapy, n (%)
Cisplatin plus paclitaxel 0 (0) 6 (13) 0.01
Cisplatin plus docetaxel 5 (9) 8 (17)
Docetaxel 1 (2) 2 (4)
Gefitinib 9 (17) 7 (16)
Overall second-line therapy 15 (28) 23 (48) 0.04
Table 3. Chemotherapy toxicity*
Cisplatin-based group (n = 54) Single-agent group (n = 48)
Toxicity
Grade 1–2 (%) Grade 3–4 (%) Grade 1–2 (%) Grade 3–4 (%)
p†
Anemia 6 (11) 13 (24) 3 (6) 3 (6) 0.04
Neutropenia 11 (20) 19 (35) 7 (15) 7 (15) 0.02
Thrombocytopenia 8 (15) 7 (13) 6 (13) 5 (10) 0.69
Nausea/Emesis 11 (29) 9 (17) 7 (15) 6 (13) 0.55
Diarrhea 3 (6) 2 (4) 2 (4) 2 (4) 0.90
Hepatic toxicity 2 (4) 1 (2) 2 (4) 0 (0) 0.34
Nephrotoxicity 2 (4) 0 (0) 0 (0) 0 (0)
Neurotoxicity 3 (6) 1 (2) 1 (2) 0 (0) 0.34
Fatigue 14 (26) 8 (15) 9 (19) 5 (10) 0.51
Neutropenia fever 2 (4) 1 (2) 0.63
*Data are presented as n (%); †comparison of grade 3 and 4 toxicity between the two groups.
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the median progression-free survival was 7.9 months
(95% CI, 5.62–10.18), compared with 5.8 months (95%
CI, 4.78–6.82) for the single-agent group (Figure 2). A sig-
nificant difference in median progression-free survival
between two groups was observed (p = 0.03).
The overall survival of patients in the two groups
according to the PS and comorbidity are summarized
in Table 4. Patients with a PS of 2 or ≥ 2 comorbidities
had a significantly worse outcome compared with pa-
tients with PS of 0 to 1 or with 1 or no comorbidity. In
the cisplatin-based combination group, median sur-
vival and 1-year survival rates were 11.6 months and
39.4%, respectively, for patients with PS of 0 to 1, and
9.0 months and 22.8%, respectively, for patients with PS
of 2 (p = 0.04). In the single-agent group, median sur-
vival and 1-year survival rates were 9.8 months and
29.8%, respectively, for patients with PS of 0 to 1, and
7.5 months and 17.5%, respectively, for patients with
PS of 2 (p = 0.06). Median survival was 11.8 months for
patients with 1 or no comorbidity, 8.6 months for pa-
tients with ≥2 comorbidities in the cisplatin-based com-
bination group (p = 0.04), and 9.5 months and 7.1
months for patients with 1 or no comorbidity and pa-
tients with ≥ 2 comorbidities in the single-agent group,
respectively (p = 0.046).
Discussion
Newer chemotherapy regimens with third-generation
cytotoxic agents in combination with cisplatin have
been shown to be better tolerated than older cisplatin-
based regimens, and some randomized trials have
also shown greater efficacy and survival benefits with
these newer combinations for the treatment of ad-
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Figure 2. Kaplan-Meier estimates of progression-free sur-
vival grouped by chemotherapy regimen. The log-rank test,
p = 0.03.
Figure 1. Kaplan-Meier estimates of overall survival grouped
by chemotherapy regimen. The log-rank test, p = 0.06.
Table 4. Overall survival by factors
Group Variable No. of patients MST (mo) 1-year (%) p
Cisplatin-based PS 0 or 1 35 11.8 40.4 0.04
PS 2 19 8.6 21.5
Single-agent PS 0 or 1 32 9.8 29.8 0.06
PS 2 16 7.5 17.5
Cisplatin-based No or 1 comorbidity 29 11.6 39.4 0.04
≥ 2 comorbidities 25 9.0 22.8
Single-agent No or 1 comorbidity 19 9.5 27.7 0.046
≥ 2 comorbidities 29 7.1 16.3
MST = median survival time; PS = performance status.
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toxicities of cisplatin-based chemotherapy regimens
and the modest survival benefit, this treatment is not
offered to many elderly patients or patients with poor
PS17. To date, the optimal regimen for elderly patients
with advanced NSCLC is still a controversial issue.
In the third-generation cytotoxic agents, a single-
agent chemotherapy regimen of vinorelbine or gem-
citabine has been investigated widely in elderly patients
with advanced NSCLC. In phase II trials specifically
designed for elderly patients with advanced NSCLC,
vinorelbine yielded overall response rates of 12–23%
and median survival times of 8.3–10 months, and gem-
citabine yielded an objective response rate of 22–33%
and median survival times of 7.4–9 months7–10. Vin-
orelbine plus gemcitabine is the most common non-
platinum chemotherapy combination used in elderly
patients. Phase II trials of vinorelbine plus gemcitabine
in elderly patients with NSCLC have shown response
rates between 18% and 65%, and a median survival
time range from 10 to 11 months18–20. These regimens
were generally well tolerated. However, there is con-
tinued controversy over the relative merits of combi-
nation versus single-agent therapy in elderly patients.
Randomized phase III trials from Italy with patients
≥ 70 years showed conflicting survival findings. In one
of these trials, the investigators found no difference in
response rates or survival times for elderly patients
with advanced NSCLC who received combination che-
motherapy with vinorelbine plus gemcitabine com-
pared with vinorelbine alone or gemcitabine alone.
Quality of life was similar for the combination versus
single agent therapy; however, toxicity was greater for
patients who received combination chemotherapy21.
Another study showed that vinorelbine and gem-
citabine combination therapy was associated with sig-
nificantly better response rate and survival in elderly
patients with advanced NSCLC than vinorelbine alone.
Combination therapy was also associated with a clear
delay in symptom progression and deterioration in
quality of life22. Based on the conflicting results of
these phase III trials, the benefit of single-agent versus
combination chemotherapy in elderly patients is an
area that needs additional study.
In our retrospective study, we evaluated the effi-
cacy of cisplatin-based combination regimen compared
with single-agent regimen (vinorelbine or gemcitabine)
in terms of response rate, toxicity and survival in elderly
patients with stage IIIB and IV NSCLC. Results showed
that the overall response rate and progression-free
survival of patients treated with cisplatin-based com-
bination regimen were substantially better than those
with single-agent therapy. Although there was no sta-
tistically significant difference in overall survival time
between two groups, cisplatin-based combination
chemotherapy showed a trend toward improved over-
all survival (p=0.06). One possible explanation for this
result is the impact of second-line therapy, which has
been shown to improve survival compared with no ther-
apy or ineffective therapy23,24. In the present study, the
rate of second-line therapy in the single-agent group
was significantly higher compared with the cisplatin-
based combination group (p=0.04). Moreover, the rate
of patients initially treated with a single-agent received
a cisplatin-based combination as second-line therapy
was markedly higher than those initially treated with a
cisplatin-based combination (p = 0.01). Another expla-
nation may be related to the bias of retrospective study.
Although the incidences of grade 3–4 anemia and
neutropenia were higher in patients treated with the
cisplatin-based combination regimen than those with
the single-agent regimen, other toxicities were mild
and generally well tolerated in two groups.
A phase III randomized trial conducted by Scagliotti
et al.25 has demonstrated that there were no significant
differences in objective response, overall survival, time
to disease progression, and quality of life between
patients treated with cisplatin plus vinorelbine and
patients treated with cisplatin plus gemcitabine for
advanced NSCLC. For the purpose of analyses, therefore,
patients treated with cisplatin plus vinorelbine and those
with cisplatin plus gemcitabine were grouped together
as the cisplatin-based combination group, and patients
treated with vinorelbine and those with gemcitabine
were considered as the single-agent group in this study.
The role of platinum-based combination chemo-
therapy in elderly patients with advanced NSCLC remains
to be clarified. A retrospective analysis of cisplatin-
based chemotherapy in NSCLC patients revealed a sig-
nificant increase in death within 30 days of starting
chemotherapy with increasing age26. It is possible that
a reduction of renal, hepatic and bone-marrow func-
tion in elderly patients increases the potential for toxi-
city. However, some retrospective analyses of elderly
patient subgroups from randomized studies support
the use of platinum-based regimens in advanced
NSCLC patients ≥70 years. These analyses showed a sim-
ilar outcome of platinum-based chemotherapy for eld-
erly patients compared with their younger counterparts
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in terms of response rate and overall survival, with a
similar toxicity and no significant adverse effects on
quality of life11–13. In addition, phase II trials of the
combination of third-generation cytotoxic agents with
cisplatin in modified schedules or attenuated doses
have been demonstrated to be an active and well-
tolerated treatment in elderly patients27,28. In the
present study, patients treated with cisplatin-based
combination regimen also received attenuated doses
of chemotherapy.
Although our data should be interpreted with cau-
tion because the results came from a retrospective
study and a relatively small number of patients were
analyzed, we conclude that it is possible that cisplatin-
based combination substantially improves the progno-
sis of elderly patients with advanced NSCLC compared
with single-agent vinorelbine or gemcitabine chemo-
therapy. The improvement obtained with cisplatin-
based combination chemotherapy can be explained
by the higher response rates and a longer overall sur-
vival and progression-free survival than single-agent
chemotherapy, along with an acceptable toxicity. In
addition, patients with good PS and fewer comorbidi-
ties had improved overall survival, regardless of che-
motherapy regimen. Therefore, PS and comorbidities
should not be ignored in the selection of elderly
patient treatment.
In summary, our results show that selected elderly
patients ≥ 70 years with advanced NSCLC may tolerate
and benefit from cisplatin-based chemotherapy. Age
itself should not preclude elderly patients from receiv-
ing cisplatin-based chemotherapy. Cisplatin-based com-
bination regimens may be considered as an option in
elderly patients with advanced NSCLC.
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